Noctrix Health vs Veeva Systems
Side-by-side comparison of AI visibility scores, market position, and capabilities
Maker of Nidra, the first FDA-authorized drug-free device for drug-refractory Restless Legs Syndrome. ~$24M ARR; acquired by ResMed for $340M (expected close June 2026).
About
Noctrix Health is a medical device company commercializing Nidra Therapy — the first and only FDA-authorized, drug-free treatment for drug-refractory Restless Legs Syndrome (RLS). The Nidra device uses Tonic Motor Activation (TOMAC) technology to deliver gentle electrical stimulation to the legs, reducing RLS symptoms without pharmaceutical side effects. The FDA granted De Novo authorization in 2023. In August 2025, Noctrix raised $33.5M in combined debt and equity to accelerate U.S. commercialization, reaching an annual revenue run rate of approximately $24M. ResMed signed an agreement in 2026 to acquire Noctrix Health for $340M, with the transaction expected to close around June 1, 2026 — Noctrix''s revenue will be reported within ResMed''s Americas Devices category post-close.
Veeva Systems (VEEV) reported $2.7B revenue in FY2025, up 14% YoY. #1 cloud platform for life sciences. ~8,000 employees. HQ: Pleasanton, CA. Market cap ~$40B.
About
Veeva Systems Inc. is the leading cloud software provider for the global life sciences industry, headquartered in Pleasanton, California. Founded in 2007 by Peter Gassner (a former Salesforce executive) and Matt Wallach, Veeva built its platform on Salesforce and later developed its own Vault cloud infrastructure. The company became a public benefit corporation (PBC) in 2021. Veeva reported revenues of $2.7B in fiscal year 2025 (ending January 2025), up 14% year-over-year, with a market capitalization of approximately $40B.
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.